New York, NY, United States of America

Fiona Mack

This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Oryzon Genomics S.a.. Active years: 2019-2026.

USPTO Granted Patents = 2 

% Patents Active = 100.0


 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2019-2026

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Fiona Mack - Innovator in Cancer Treatment

Introduction

Fiona Mack is a prominent inventor based in New York, NY (US). She has made significant contributions to the field of cancer treatment through her innovative research and development of therapeutic combinations.

Latest Patents

Fiona holds 1 patent for her invention titled "Combinations of LSD1 inhibitors for use in the treatment of solid tumors." This invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredients or pharmaceutically acceptable salts. The combinations are particularly useful for treating neoplastic diseases, such as cancer, with a focus on small cell lung cancer (SCLC).

Career Highlights

Fiona Mack has established herself as a key figure in the pharmaceutical industry. Her work at Oryzon Genomics S.A. has been instrumental in advancing cancer therapies. She is dedicated to improving treatment options for patients suffering from various forms of cancer.

Collaborations

Fiona collaborates with notable colleagues, including Mark D Demario and Tamara Maes. Their combined expertise enhances the research and development efforts at Oryzon Genomics S.A.

Conclusion

Fiona Mack's innovative work in cancer treatment exemplifies the impact of dedicated inventors in the medical field. Her contributions continue to pave the way for advancements in therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…